Akero Therapeutics announced the appointment of Scott Gangloff as Chief Technology Officer. Most recently, Gangloff served as Vice President, Global Biopharmaceutical Development, at Incyte Corporation
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics reinstated with a Neutral at BofA
- JPMorgan SMid cap biotech analyst to hold analyst/industry conference call
- Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
- 89bio price target raised to $37 from $29 at Evercore ISI